Jacek Skarbinski, MD

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

510-418-2196 (phone)
jacek.skarbinski@kp.org

Jacek Skarbinski, MD, is a research scientist at the Kaiser Permanente Division of Research and a practicing infectious diseases and HIV medicine specialist at Kaiser Permanente, Oakland Medical Center. In addition, he serves as the Program Director of the Kaiser Permanente Northern California HIV Fellowship. He is part of The Permanente Medical Group Physician Researcher Program and serves as co-chair of the Kaiser Permanente Northern California COVID-19 Clinical Research Coordinating Team.

Before joining The Permanente Medical Group in 2016, Dr. Skarbinski served with the Centers for Disease Control and Prevention (CDC) in various epidemiology and leadership roles. His CDC research addressed the epidemiology, diagnosis, treatment and prevention of infectious diseases with a focus on malaria, HIV, tuberculosis, and influenza. His current research interests include clinical trials, observational studies, and implementation science in a broad range of infectious diseases including HIV, tuberculosis, and COVID-19.

Dr. Skarbinski earned his MD at Stanford University School of Medicine after completing his BA at Cornell University. He completed his internal medicine residency at the University of California-San Francisco in the San Francisco General Internal Medicine Primary Care Track, served as an Epidemic Intelligence Service Officer at the CDC and completed an infectious diseases fellowship at Emory University School of Medicine.

Current Position(s):

Research Scientist III, Division of Research, Kaiser Permanente Northern California
Senior Physician, Department of Infectious Diseases, The Permanente Medical Group, Oakland Medical Center
Program Director, Kaiser Permanente Northern California HIV Fellowship

Section Affiliations:

Infectious Diseases

Primary Research Interests:

HIV
Tuberculosis
COVID-19
Chronic fatigue syndrome
Clinical trials
Infectious diseases epidemiology
Delivery and implementation science

Studies

Monitoring shared variation in genomes of SARS-CoV-2 among persons with COVID-19 with and without vaccination in Northern California

We are studying the genomes of SARS-CoV-2 in persons with COVID-19 with and without vaccination to identify and describe variants circulating within our patients, including variants of concern (such as Delta or Omicron. We also are assessing which shared genomic variations are associated with a greater risk for infection (symptomatic and asymptomatic) and severe outcomes (such as hospitalization, intensive care unit use, and death), and whether certain subpopulations, such as those with certain medical comorbidities, might be at a greater risk for infection and severe outcomes from identified variants. Through modeling, we are investigating whether and which mutations result in decreased vaccine effectiveness for prevention of infection and severe outcomes, and which may require a booster or an updated vaccine.
Investigator: Skarbinski, Jacek
Funder:

Tuberculosis Epidemiologic Studies Consortium III

The goals of this study are to identify primary care settings that serve non-U.S.born persons at risk for latent tuberculosis infection and tuberculosis disease; collect retrospective and prospective electronic medical record data; design and implement clinical care-based interventions to improve performance measures across the latent tuberculosis infection care cascade; and monitor and evaluate intervention performance over time to identify efficient and effective strategies
Investigator: Skarbinski, Jacek
Funder: Centers for Disease Control and Prevention

Tuberculosis Epidemiologic Studies Consortium III

This study will identify primary care systems and settings that serve non-U.S.-born persons at risk for latent tuberculosis infection (LTBI) and tuberculosis disease; collect retrospective and prospective electronic medical record data; design and implement clinical care-based interventions to improve performance measures across the LTBI care cascade; and monitor and evaluate intervention performance over time to identify efficient and effective strategies.
Investigator: Skarbinski, Jacek
Funder: Centers for Disease Control and Prevention

Comparing the frequency of SARS-CoV-2 variants of concern among vaccinated and unvaccinated COVID-19 cases

In partnership with the California Emerging Infection Program and the California Department of Public Health, Kaiser Permanente Northern California will contribute to statewide whole genome sequencing efforts for surveillance for SARS-CoV-2 variants of concern by submitting samples from all vaccine breakthrough cases, a subset of hospitalized cases, and a set of matched controls. Sequencing will be done in a central laboratory and sequence data reported to public health authorities.
Investigator: Skarbinski, Jacek
Funder: Centers for Disease Control and Prevention

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) Treatment of COVID-19 in an Outpatient Setting

This clinical trial will evaluate treatment with IV administered remdesivir in an outpatient setting in patients with COVID-19 who are at risk for disease progression.
Investigator: Skarbinski, Jacek
Funder: Gilead Sciences, Inc.

SARS-CoV-2 Serological Antibody Testing for Disease Surveillance and Clinical Use

This study will assess the sero-prevalence and sero-incidence of SARS-CoV-2 infection in Kaiser Permanente Northern California and assess correlates of exposure and immunity among KPNC members.
Investigator: Skarbinski, Jacek
Funder: National Cancer Institute

Highlighted Publications

Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States

Author(s): Lee-Rodriguez C; Wada PY; Hung YY; Skarbinski J

JAMA Netw Open. 2020 Sep 01;3(9):e2014481. Epub 2020-09-01.

Current Position(s):

Section Affiliations:

Primary Research Interests:

Studies

Monitoring shared variation in genomes of SARS-CoV-2 among persons with COVID-19 with and without vaccination in Northern California

Tuberculosis Epidemiologic Studies Consortium III

Tuberculosis Epidemiologic Studies Consortium III

Comparing the frequency of SARS-CoV-2 variants of concern among vaccinated and unvaccinated COVID-19 cases

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) Treatment of COVID-19 in an Outpatient Setting

SARS-CoV-2 Serological Antibody Testing for Disease Surveillance and Clinical Use

Highlighted Publications

Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States

Service Delivery and Patient Outcomes in Ryan White HIV/AIDS Program-Funded and -Nonfunded Health Care Facilities in the United States.

Human immunodeficiency virus transmission at each step of the care continuum in the United States.

Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys.

Differences in human immunodeficiency virus care and treatment among subpopulations in the United States.

Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial.

The burden of out-of-pocket payments for health care in Tbilisi, Republic of Georgia.

Publications

Population-based assessment of risks for severe COVID-19 disease outcomes

Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System

Rationale and Design of the Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults (MITIGATE)

Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization

Burden of Active Tuberculosis in an Integrated Health Care System, 1997-2016: Incidence, Mortality, and Excess Health Care Utilization

Comparison of msp genotyping and a 24 SNP molecular assay for differentiating Plasmodium falciparum recrudescence from reinfection

Epidemiology, detection, and management of tuberculosis among end-stage renal disease patients

Latent tuberculous infection testing among HIV-infected persons in clinical care, United States, 2010-2012.

Qualifications, Demographics, Satisfaction, and Future Capacity of the HIV Care Provider Workforce in the United States, 2013-2014.

Nearly Half Of US Adults Living With HIV Received Federal Disability Benefits In 2009.

Service Delivery and Patient Outcomes in Ryan White HIV/AIDS Program-Funded and -Nonfunded Health Care Facilities in the United States.

Ryan White HIV/AIDS Program Assistance and HIV Treatment Outcomes.

Human immunodeficiency virus transmission at each step of the care continuum in the United States.

Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys.

Differences in human immunodeficiency virus care and treatment among subpopulations in the United States.

Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi.

Impact of health facility-based insecticide treated bednet distribution in Malawi: progress and challenges towards achieving universal coverage.

Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009.

Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial.

The burden of out-of-pocket payments for health care in Tbilisi, Republic of Georgia.